Pfizer and BioNTech To Supply Qatar With Their bnt162 Mrna-Based Vaccine Candidate Against Sars-Cov-2

Press release
Published September 29th, 2020 - 10:05 GMT
Pfizer and BioNTech To Supply Qatar With Their bnt162 Mrna-Based Vaccine Candidate Against Sars-Cov-2
• Supply to be provided by the end of 2020 to 2021, subject to necessary regulatory approvals
Pfizer Inc. and BioNTech SE today announced an agreement with the Ministry of Public Health in Qatar

Pfizer Inc. and BioNTech SE today announced an agreement with the Ministry of Public Health in Qatar to supply their BNT162 mRNA-based vaccine candidate against SARS-CoV-2, subject to clinical success and regulatory approval, by the end of 2020 to 2021.

Financial details of the agreement were not disclosed. As requested by the Vaccine Procurement Taskforce Team, on behalf the Government of Qatar, deliveries are planned for the end of 2020 to 2021, subject to clinical success and local regulatory approval.

“We are deeply honored to work with the Qatar government and to marshal our scientific and manufacturing resources toward our shared goal of bringing a potential COVID-19 vaccine to the Qatar people as quickly as possible,” said Lindsey Dietschi, Pfizer Gulf Cluster Lead. “In the face of this global health crisis, Pfizer’s purpose – breakthroughs that change patients’ lives – has taken on an even greater urgency. Our hope is that, subject to clinical and regulatory success, our vaccine will help make this happen.”

“I would like to thank the Qatar government for its support and putting trust in our ability to develop a vaccine that, we believe, has the potential to help address this global pandemic threat. Our goal remains to create a global supply of a safe and effective COVID-19 vaccine for many people around the world, as quickly as we can,” said Sean Marett, Chief Business and Chief Commercial Officer at BioNTech.

Dr. Aisha Ibrahim AlAnsari, the Chair of the Vaccine Procurement Taskforce commented: “The State of Qatar has spared no effort in ensuring a rapid and timely response in this fight against the novel coronavirus COVID-19. Our citizens and residents are our utmost priority and we are taking all the necessary steps to ensure the timely availability of a safe and effective vaccine against Covid-19. With this partnership, we continue our efforts to combat the virus.”

In addition to engagements with governments, Pfizer and BioNTech have provided an expression of interest for possible supply to the COVAX Facility, a mechanism established by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and World Health Organization (WHO) that aims to provide governments, including those in the emerging markets, with early access to a large portfolio of COVID-19 candidate vaccines using a range of technology platforms, produced by multiple manufacturers across the world.

Background Information


At Pfizer, it applies science and its global resources to improve health and well-being at every stage of life.  It strives to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals. Its diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world’s best-known consumer products.  

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of its time. Consistent with its responsibility as the world’s leading biopharmaceutical company, it also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on them.  

Check out our PR service

Signal PressWire is the world’s largest independent Middle East PR distribution service.


Sign up to our newsletter for exclusive updates and enhanced content